Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside

被引：46
|
作者：
Bruno, B
Giaccone, L
Rotta, M
Anderson, K
Boccadoro, M
机构：
[1] Univ Turin, Div Ematol, Osped S Giovanni Battist, I-10126 Turin, Italy
[2] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
来源：
LEUKEMIA | 2005年 / 19卷 / 10期
关键词：
mutliple myeloma; new drugs; signaling pathways;
D O I：
10.1038/sj.leu.2403905
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Multiple myeloma remains an incurable plasma cell neoplasm. New insights into its pathogenesis have identified signaling pathways that have become potential therapeutic targets. It has clearly been established that intracellular regulatory proteins and interactions between malignant plasma cells and the bone marrow microenvironment play an important role in their survival and drug resistance. Several new agents associated with molecular targets are currently being investigated to design new treatment strategies aimed at prolonging survival and improving quality of life. This review illustrates their mechanisms of action and the possible future clinical applications.
引用
收藏
页码：1729 / 1738
页数：10
相关论文
共 50 条
  • [1] Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside
    B Bruno
    L Giaccone
    M Rotta
    K Anderson
    M Boccadoro
    Leukemia, 2005, 19 : 1729 - 1738
  • [2] Exosomes in multiple myeloma: from bench to bedside
    Menu, Eline
    Vanderkerken, Karin
    BLOOD, 2022, 140 (23) : 2429 - 2442
  • [3] Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma
    Berdeja, Jesus G.
    Laubach, Jacob P.
    Richter, Joshua
    Stricker, Steve
    Spencer, Andrew
    Richardson, Paul G.
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : 752 - 765
  • [4] Clinical Translation in Multiple Myeloma: From Bench to Bedside
    Laubach, Jacob
    Hideshima, Teru
    Richardson, Paul
    Anderson, Kenneth
    SEMINARS IN ONCOLOGY, 2013, 40 (05) : 549 - 553
  • [5] Pathogenesis of bone disease in multiple myeloma: from bench to bedside
    Terpos, Evangelos
    Ntanasis-Stathopoulos, Ioannis
    Gavriatopoulou, Maria
    Dimopoulos, Meletios A.
    BLOOD CANCER JOURNAL, 2018, 8
  • [6] Histone deacetylase inhibitors in multiple myeloma: from bench to bedside
    Harada, Takeshi
    Hideshima, Teru
    Anderson, Kenneth C.
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 104 (03) : 300 - 309
  • [7] From the bench to the bedside: emerging new treatments in multiple myeloma
    Hayden, Patrick J.
    Mitsiades, Constantine S.
    Anderson, Kenneth C.
    Richardson, Paul G.
    TARGETED ONCOLOGY, 2008, 3 (01) : 19 - 29
  • [8] From the bench to the bedside: emerging new treatments in multiple myeloma
    Patrick J. Hayden
    Constantine S. Mitsiades
    Kenneth C. Anderson
    Paul G. Richardson
    Targeted Oncology, 2008, 3 : 19 - 29
  • [9] From the bench to the bedside: emerging new treatments in multiple myeloma
    Mitsiades, Constantine S.
    Hayden, Patrick J.
    Anderson, Kenneth C.
    Richardson, Paul G.
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2007, 20 (04) : 797 - 816
  • [10] Pathogenesis of bone disease in multiple myeloma: from bench to bedside
    Evangelos Terpos
    Ioannis Ntanasis-Stathopoulos
    Maria Gavriatopoulou
    Meletios A. Dimopoulos
    Blood Cancer Journal, 8
12345